Journal of Reconstructive Urology

.: ORIGINAL RESEARCH
The Active Surveillance for Low-risk Prostate Cancer: Case Series of Single Center
Düşük Riskli Prostat Kanserleri İçin Aktif İzlem: Tek Merkezin Olgu Serisi
İlker AKARKENa, Harun BALa, Hüseyin TARHANa, Hasan DELİKTAŞa, Hayrettin ŞAHİNa
aDepartment of Urology, Muğla Sıtkı Koçman University Faculty of Medicine, Muğla, TURKEY
J Reconstr Urol. 2021;11(2):73-8
doi: 10.5336/urology.2021-81636
Article Language: EN
Full Text
ABSTRACT
 Objective: Up to 80% of prostate cancer cases are indolent that pose a minimal risk for morbidity and mortality throughout the life of the patient. Cancer-specific survival of the patients just followed up and those who received curative treatment were found to be similar, especially in the low-risk category. Active surveillance was described to preserve the quality of life of the patients and to protect them from the side effects of curative treatments. It has become increasingly used in low and very low risk. Although there are many studies on this subject with a large number of patients in the literature, we aimed to present our first results in this study. Material and Methods: The data of the patients, that were included in the active surveillance program between January 2012 and April 2020, were retrospectively analyzed. The patients were diagnosed with low-risk prostate cancer according to D'Amico criteria (International Society of Urological Pathology grade group 1, prostate-specific antigen <10 ng/mL, stage cT1c-T2a) via a minimum 12 core transrectal ultrasound guided prostate biopsy due to suspicious digital rectal examination and/or prostate-specific antigen elevation. Results: Thirty-six patients, who preferred active surveillance were included in the study. The mean age and prostate-specific antigen values of the patients were 66.38±8.02 years and 5.63±2.3 ng/mL, respectively. The median follow- up was 18.4 (minimum 1.63-maximum 82.4) months. In the initial biopsy, the cancer was detected in one core in 25 (69.4%), two cores in 10 (27.8%), and three cores in one (2.8%) of the patients. A total of 7 (19.4%) cases had received curative treatment. 3 cases had progression in pathological parameters and 4 cases chose to have active treatment. Conclusion: Our initial results with active surveillance are similar to the literature. Per the literature, the number of patients that chose active surveillance has increased.

Keywords: Prostate biopsy; cancer; surveillance
ÖZET
 Prostat kanseri vakalarının %80 kadarı indolenttir. Hastanın yaşamı boyunca morbidite ve mortalite için minimum risk oluştururlar. Sadece takip edilenler ile küratif tedavi alan hastaların kansere özgü sağ kalımları, özellikle düşük risk kategorisinde benzer bulunmuştur. Aktif izlem, hastaların yaşam kalitesini korumanın yanı sıra onları küratif tedavilerin yan etkilerinden korumak için tanımlandı. Aktif izlem, düşük ve çok düşük riskte giderek daha fazla kullanılmaktadır. Literatürde, bu konuda çok sayıda hasta ile birçok çalışma olsa da çalışmamızda ilk sonuçlarımızı sunmayı amaçladık. Gereç ve Yöntemler: Ocak 2012 ile Nisan 2020 tarihleri arasında aktif izlem programına alınan hastaların verileri retrospektif olarak değerlendirildi. Hastalara, şüpheli dijital rektal muayene ve/veya prostat-spesifik antijen seviyesinin yükselmesi nedeniyle minimum 12 kor transrektal ultrason kılavuzluğunda prostat biyopsisi yapılmış olup, D'Amico kriterlerine göre düşük riskli prostat kanseri (International Society of Urological Pathology grade group 1, prostat-spesifik antijen <10 ng/mL, evre cT1c-T2a) teşhisi konulmuştur. Bulgular: Çalışmaya, aktif izlemi tercih eden 36 hasta dâhil edildi. Hastaların ortalama yaş ve prostat spesifik antijen değerleri sırasıyla 66,38±8,02 yıl ve 5,63±2,3 ng/mL idi. Ortanca takip süresi 18,4 (minimum 1,63-maksimum 82,4) aydı. İlk biyopside hastaların 25'inde (%69,4) 1, 10'unda (%27,8) 2 ve 1'inde (%2,8) 3 odakta kanser tespit edilmişti. Toplam 7 (%19,4) vaka, küratif tedavi almıştı. Üç vaka, patolojik parametrelerde ilerleme gösterdi ve 4 vaka, aktif tedavi olmayı seçti. Sonuç: Aktif izlemde ilk sonuçlarımız, literatür ile benzerdir ve kliniğimizde, aktif izlemi tercih eden hasta sayısı artmaktadır.

Anahtar Kelimeler: Prostat biyopsisi; kanser; izlem
REFERENCES:
  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7-30. [Crossref]  [PubMed] 
  2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424. Erratum in: CA Cancer J Clin. 2020;70(4): 313. [Crossref]  [PubMed] 
  3. Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA. 2005;293(17):2095-101. [Crossref]  [PubMed] 
  4. Cooperberg MR, Broering JM, Carroll PR. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol. 2010;28(7):1117-23. [Crossref]  [PubMed]  [PMC] 
  5. Wei JT, Dunn RL, Sandler HM, McLa ughlin PW, Montie JE, Litwin MS, et al. Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer. J Clin Oncol. 2002;20(2):557-66. [Crossref]  [PubMed] 
  6. Vickers A, Bennette C, Steineck G, Adami HO, Johansson JE, Bill-Axelson A, et al. Individualized estimation of the benefit of radical prostatectomy from the Scandinavian Prostate Cancer Group randomized trial. Eur Urol. 2012;62(2):204-9. [Crossref]  [PubMed]  [PMC] 
  7. Bill-Axelson A, Holmberg L, Garmo H, Rider JR, Taari K, Busch C, et al. Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J Med. 2014;370(10):932-42. [Crossref]  [PubMed]  [PMC] 
  8. Choo R, Klotz L, Danjoux C, Morton GC, DeBoer G, Szumacher E, et al. Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. J Urol. 2002;167(4):1664-9. [Crossref]  [PubMed] 
  9. Loeb S, Folkvaljon Y, Curnyn C, Robinson D, Bratt O, Stattin P. Uptake of active surveillance for very-low-risk prostate cancer in Sweden. JAMA Oncol. 2017;3(10):1393-8. [Crossref]  [PubMed]  [PMC] 
  10. National Comprehensive Cancer Network [Internet]. Copyright © 2021 National Comprehensive Cancer Network [Cited 14 April 2020]. NCCN Guidelines: Prostate Cancer (Version 1.2020). Available from: [Link] 
  11. European Association of Urology [Internet]. © Copyright 2021 Uroweb [Cited 15 April 2020]. EAU Guidelines: Prostate Cancer | Uroweb. Available from: [Link] 
  12. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280(11):969-74. [Crossref]  [PubMed] 
  13. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Zappa M, Nelen V, et al; ERSPC Investigators. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet. 2014;384(9959):2027-35. [Crossref]  [PubMed]  [PMC] 
  14. Welch HG, Black WC. Overdiagnosis in cancer. J Natl Cancer Inst. 2010;102(9):605-13. [Crossref]  [PubMed] 
  15. Wilt TJ, Brawer MK, Jones KM, Barry MJ, Aronson WJ, Fox S, et al; Prostate Cancer Intervention versus Observation Trial (PIVOT) Study Group. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med. 2012;367(3):203-13. Erratum in: N Engl J Med. 2012;367(6):582. [Crossref]  [PubMed]  [PMC] 
  16. Whiting PF, Moore TH, Jameson CM, Davies P, Rowlands MA, Burke M, et al. Symptomatic and quality-of-life outcomes after treatment for clinically localised prostate cancer: a systematic review. BJU Int. 2016;118(2):193-204. [Crossref]  [PubMed] 
  17. Donovan JL, Hamdy FC, Lane JA, Mason M, Metcalfe C, Walsh E, et al; ProtecT Study Group*. Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med. 2016;375(15):1425-37. [PubMed]  [PMC] 
  18. Leapman MS, Cowan JE, Nguyen HG, Shinohara KK, Perez N, Cooperberg MR, et al. Active surveillance in younger men with prostate cancer. J Clin Oncol. 2017;35(17): 1898-904. [Crossref]  [PubMed]  [PMC] 
  19. Klotz L, Vesprini D, Sethukavalan P, Jethava V, Zhang L, Jain S, et al. Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J Clin Oncol. 2015;33(3): 272-7. [Crossref]  [PubMed] 
  20. Reese AC, Landis P, Han M, Epstein JI, Carter HB. Expanded criteria to identify men eligible for active surveillance of low risk prostate cancer at Johns Hopkins: a preliminary analysis. J Urol. 2013;190(6):2033-8. [Crossref]  [PubMed] 
  21. Soloway MS, Soloway CT, Eldefrawy A, Acosta K, Kava B, Manoharan M. Careful selection and close monitoring of low-risk prostate cancer patients on active surveillance minimizes the need for treatment. Eur Urol. 2010;58(6):831-5. [Crossref]  [PubMed] 
  22. Musunuru HB, Yamamoto T, Klotz L, Ghanem G, Mamedov A, Sethukavalan P, et al. Active surveillance for intermediate risk prostate cancer: survival outcomes in the Sunnybrook experience. J Urol. 2016;196(6):1651-8. [Crossref]  [PubMed] 
  23. van der Poel HG, van den Bergh RC. Difference of opinion - Active surveillance in intermediate risk prostate cancer: is it safe? Opinion: Yes. Int Braz J Urol. 2016;42(3):413-7. [Crossref]  [PubMed]  [PMC] 
  24. Macleod LC, Ellis WJ, Newcomb LF, Zheng Y, Brooks JD, Carroll PR, et al. Timing of adverse prostate cancer reclassification on first surveillance biopsy: results from the canary prostate cancer active surveillance study. J Urol. 2017;197(4):1026-33. [Crossref]  [PubMed]  [PMC] 
  25. Mamawala MM, Rao K, Landis P, Epstein JI, Trock BJ, Tosoian JJ, et al. Risk prediction tool for grade re-classification in men with favourable-risk prostate cancer on active surveillance. BJU Int. 2017;120(1):25-31. [Crossref]  [PubMed] 
  26. Davis JW, Ward JF 3rd, Pettaway CA, Wang X, Kuban D, Frank SJ, et al. Disease reclassification risk with stringent criteria and frequent monitoring in men with favourable-risk prostate cancer undergoing active surveillance. BJU Int. 2016;118(1):68-76. [Crossref]  [PubMed]  [PMC] 
  27. Druskin SC, Mamawala M, Tosoian JJ, Epstein JI, Pavlovich CP, Carter HB, et al. Older age predicts biopsy and radical prostatectomy grade reclassification to aggressive prostate cancer in men on active surveillance. J Urol. 2019;201(1):98-104. [Crossref]  [PubMed] 
  28. Filson CP, Natarajan S, Margolis DJ, Huang J, Lieu P, Dorey FJ, et al. Prostate cancer detection with magnetic resonance-ultrasound fusion biopsy: The role of systematic and targeted biopsies. Cancer. 2016;122(6):884-92. [Crossref]  [PubMed]  [PMC] 
  29. Siddiqui MM, Rais-Bahrami S, Truong H, Stamatakis L, Vourganti S, Nix J, et al. Magnetic resonance imaging/ultrasound-fusion biopsy significantly upgrades prostate cancer versus systematic 12-core transrectal ultrasound biopsy. Eur Urol. 2013;64(5):713-9. [Crossref]  [PubMed]  [PMC] 
  30. Da Rosa MR, Milot L, Sugar L, Vesprini D, Chung H, Loblaw A, et al. A prospective comparison of MRI-US fused targeted biopsy versus systematic ultrasound-guided biopsy for detecting clinically significant prostate cancer in patients on active surveillance. J Magn Reson Imaging. 2015;41(1):220-5. [Crossref]  [PubMed] 
  31. Schulman AA, Sze C, Tsivian E, Gupta RT, Moul JW, Polascik TJ. The contemporary role of multiparametric magnetic resonance imaging in active surveillance for prostate cancer. Curr Urol Rep. 2017;18(7):52. [Crossref]  [PubMed] 
  32. Womble PR, Montie JE, Ye Z, Linsell SM, Lane BR, Miller DC; Michigan Urological Surgery Improvement Collaborative. Contemporary use of initial active surveillance among men in Michigan with low-risk prostate cancer. Eur Urol. 2015;67(1):44-50. [Crossref]  [PubMed] 
  33. Van Hemelrijck M, Ji X, Helleman J, Roobol MJ, van der Linden W, Nieboer D, et al; Members of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance GAP3 consortium; Members of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance GAP3 consortium. Reasons for discontinuing active surveillance: assessment of 21 centres in 12 countries in the movember GAP3 consortium. Eur Urol. 2019;75(3):523-31. [PubMed] 
  34. Soydan H, Dursun F, Yılmaz Ö, Okçelik S, Ateş F, Karademir K. Our results of active surveillance for localized prostate cancer patients. Turk J Urol. 2013;39(1):1-5. [Crossref]  [PubMed]  [PMC] 
  35. Bayar G, Horasanlı K, Acinikli H, Tanrıverdi O, Dalkılıç A, Arısan S. The importance of active surveillance, and immediate re-biopsy in low-risk prostate cancer: The largest series from Turkey. Turk J Urol. 2016;42(3):140-4. [Crossref]  [PubMed]  [PMC] 

.: Up To Date

Login

 Forgot your password?

 New Registration  

Contact

Ortadoğu Reklam Tanıtım Yayıncılık Turizm Eğitim İnşaat Sanayi ve Ticaret A.Ş.

.: Address

Turkocagi Caddesi No:30 06520 Balgat / ANKARA
Phone: +90 312 286 56 56
Fax: +90 312 220 04 70
E-mail: info@turkiyeklinikleri.com

.: Manuscript Editing Department

Phone: +90 312 286 56 56/ 2
E-mail: yaziisleri@turkiyeklinikleri.com

.: English Language Redaction

Phone: +90 312 286 56 56/ 145
E-mail: tkyayindestek@turkiyeklinikleri.com

.: Marketing Sales-Project Department

Phone: +90 312 286 56 56/ 142
E-mail: reklam@turkiyeklinikleri.com

.: Subscription and Public Relations Department

Phone: +90 312 286 56 56/ 118
E-mail: abone@turkiyeklinikleri.com

.: Customer Services

Phone: +90 312 286 56 56/ 118
E-mail: satisdestek@turkiyeklinikleri.com

1. TERMS OF USE

1.1. To use the web pages with http://www.turkiyeklinikleri.com domain name or the websites reached through the sub domain names attached to the domain name (They will be collectively referred as "SITE"), please read the conditions below. If you do not accept these terms, please cease to use the "SITE." "SITE" owner reserves the right to change the information on the website, forms, contents, the "SITE," "SITE" terms of use anytime they want.

1.2. The owner of the "SITE" is Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. (From now on it is going to be referred as "Turkiye Klinikleri", shortly) and it resides at Turkocagi cad. No:30, 06520 Balgat Ankara. The services in the "SITE" are provided by "Turkiye Klinikleri."

1.3. Anyone accessing the "SITE" with or without a fee whether they are a natural person or a legal identity is considered to agree these terms of use. In this contract hereby, "Turkiye Klinikleri" may change the stated terms anytime. These changes will be published in the "SITE" periodically and they will be valid when they are published. Any natural person or legal identity benefiting from and reaching to the "SITE" are considered to be agreed to any change on hereby contract terms done by "Turkiye Klinikleri."

1.4. The "Terms of Use" hereby is published in the website with the last change on March 30th 2014 and the "SITE" is activated by enabling the access to everyone. The "Terms of Use" hereby is also a part of the any "USER Contract" was and/or will be done with the users using "Turkiye Klinikleri" services with or without a fee an inseparable.

2. DEFINITIONS

2.1. "SITE": A website offering different kind of services and context with a certain frame determined by "Turkiye Klinikleri" and it is accessible on-line on http://www.turkiyeklinikleri.com domain name and/or subdomains connected to the domain name.

2.2. USER: A natural person or a legal identity accessing to the "SITE" through online settings.

2.3. LINK: A link enabling to access to another website through the "SITE", the files, the context or through another website to the "SITE", the files and the context.

2.4. CONTEXT: Any visual, literary and auditory images published in the "Turkiye Klinikleri", "SITE" and/or any website or any accessible information, file, picture, number/figures, price, etc.

2.5. "USER CONTRACT": An electronically signed contract between a natural or a legal identity benefiting from special services "Turkiye Klinikleri" will provide and "Turkiye Klinikleri".

3. SCOPE OF THE SERVICES

3.1. "Turkiye Klinikleri" is completely free to determine the scope and quality of the services via the "SITE".

3.2. To benefit the services of "Turkiye Klinikleri" "SITE", the "USER" must deliver the features that will be specified by "Turkiye Klinikleri". "Turkiye Klinikleri" may change this necessity any time single-sided.

3.3. Not for a limited number, the services "Turkiye Klinikleri" will provide through the "SITE" for a certain price or for free are;

- Providing scientific articles, books and informative publications for health industry.

- Providing structural, statistical and editorial support to article preparation stage for scientific journals.

4. GENERAL PROVISIONS

4.1. "Turkiye Klinikleri" is completely free to determine which of the services and contents provided in the "SITE" will be charged.

4.2. People benefiting from the services provided by "Turkiye Klinikleri" and using the website can use the "SITE" only according to the law and only for personal reasons. Users have the criminal and civil liability for every process and action they take in the "SITE". Every USER agrees, declares and undertakes that they will not proceed by any function or action infringement of rights of "Turkiye Klinikleri"s and/or other third parties', they are the exclusive right holder on usage, processing, storage, made public and revealing any written, visual or auditory information reported to Turkiye Klinikleri" and/or "SITE" to the third parties. "USER" agrees and undertakes that s/he will not duplicate, copy, distribute, process, the pictures, text, visual and auditory images, video clips, files, databases, catalogs and lists within the "SITE", s/he will not be using these actions or with other ways to compete with "Turkiye Klinikleri", directly or indirectly.

4.3. The services provided and the context published within the "SITE" by third parties is not under the responsibility of "Turkiye Klinikleri", institutions collaborated with "Turkiye Klinikleri", "Turkiye Klinikleri" employee and directors, "Turkiye Klinikleri" authorized salespeople. Commitment to accuracy and legality of the published information, context, visual and auditory images provided by any third party are under the full responsibility of the third party. "Turkiye Klinikleri" does not promise and guarantee the safety, accuracy and legality of the services and context provided by a third party.

4.4. "USER"s cannot act against "Turkiye Klinikleri", other "USER"s and third parties by using the "SITE". "Turkiye Klinikleri" has no direct and/or indirect responsibility for any damage a third party suffered or will suffer regarding "USER"s actions on the "SITE" against the rules of the hereby "Terms of Use" and the law.

4.5. "USER"s accept and undertake that the information and context they provided to the "SITE" are accurate and legal. "Turkiye Klinikleri" is not liable and responsible for promising and guaranteeing the verification of the information and context transmitted to "Turkiye Klinikleri" by the "USER"s, or uploaded, changed and provided through the "SITE" by them and whether these information are safe, accurate and legal.

4.6. "USER"s agree and undertake that they will not perform any action leading to unfair competition, weakening the personal and commercial credit of "Turkiye Klinikleri" and a third party,  encroaching and attacking on personal rights within the "SITE" in accordance with the Turkish Commercial Code Law.

4.7. "Turkiye Klinikleri" reserves the right to change the services and the context within the "SITE"  anytime. "Turkiye Klinikleri" may use this right without any notification and timelessly. "USER"s have to make the changes and/or corrections "Turkiye Klinikleri" required immediately. Any changes and/or corrections that are required by "Turkiye Klinikleri", may be made by "Turkiye Klinikleri" when needed. Any harm, criminal and civil liability resulted or will result from changes and/or corrections required by "Turkiye Klinikleri" and were not made on time by the "USER"s belongs completely to the users.

4.8. "Turkiye Klinikleri" may give links through the "SITE" to other websites and/or "CONTEXT"s and/or folders that are outside of their control and owned and run by third parties. These links are provided for ease of reference only and do not hold qualification for support the respective web SITE or the admin or declaration or guarantee for the information inside. "Turkiye Klinikleri" does not hold any responsibility over the web-sites connected through the links on the "SITE", folders and context, the services or products on the websites provided through these links or their context.

4.9. "Turkiye Klinikleri" may use the information provided to them by the "USERS" through the "SITE" in line with the terms of the "PRIVACY POLICY" and "USER CONTRACT". It may process the information or classify and save them on a database. "Turkiye Klinikleri" may also use the USER's or visitor's identity, address, e-mail address, phone number, IP number, which sections of the "SITE" they visited, domain type, browser type, date and time information to provide statistical evaluation and customized services.

5. PROPRIETARY RIGHTS

5.1. The information accessed through this "SITE" or provided by the users legally and all the elements (including but not limited to design, text, image, html code and other codes) of the "SITE" (all of them will be called as studies tied to "Turkiye Klinikleri"s copyrights) belongs to "Turkiye Klinikleri". Users do not have the right to resell, process, share, distribute, display or give someone permission to access or to use the "Turkiye Klinikleri" services, "Turkiye Klinikleri" information and the products under copyright protection by "Turkiye Klinikleri". Within hereby "Terms of Use" unless explicitly permitted by "Turkiye Klinikleri" nobody can reproduce, process, distribute or produce or prepare any study from those under "Turkiye Klinikleri" copyright protection.

5.2. Within hereby "Terms of Use", "Turkiye Klinikleri" reserves the rights for "Turkiye Klinikleri" services, "Turkiye Klinikleri" information, the products associated with "Turkiye Klinikleri" copyrights, "Turkiye Klinikleri" trademarks, "Turkiye Klinikleri" trade looks or its all rights for other entity and information it has through this website unless it is explicitly authorized by "Turkiye Klinikleri".

6. CHANGES IN THE TERMS OF USE

"Turkiye Klinikleri" in its sole discretion may change the hereby "Terms of Use" anytime announcing within the "SITE". The changed terms of the hereby "Terms of Use" will become valid when they are announced. Hereby "Terms of Use" cannot be changed by unilateral declarations of users.

7. FORCE MAJEURE

"Turkiye Klinikleri" is not responsible for executing late or never of this hereby "Terms of Use", privacy policy and "USER Contract" in any situation legally taken into account as force majeure. Being late or failure of performance or non-defaulting of this and similar cases like this will not be the case from the viewpoint of "Turkiye Klinikleri", and "Turkiye Klinikleri" will not have any damage liability for these situations. "Force majeure" term will be regarded as outside of the concerned party's reasonable control and any situation that "Turkiye Klinikleri" cannot prevent even though it shows due diligence. Also, force majeure situations include but not limited to natural disasters, rebellion, war, strike, communication problems, infrastructure and internet failure, power cut and bad weather conditions.

8. LAW AND AUTHORISATION TO FOLLOW

Turkish Law will be applied in practicing, interpreting the hereby "Terms of Use" and managing the emerging legal relationships within this "Terms of Use" in case of finding element of foreignness, except for the rules of Turkish conflict of laws. Ankara Courts and Enforcement Offices are entitled in any controversy happened or may happen due to hereby contract.

9. CLOSING AND AGREEMENT

Hereby "Terms of Use" come into force when announced in the "SITE" by "Turkiye Klinikleri". The users are regarded to agree to hereby contract terms by using the "SITE". "Turkiye Klinikleri" may change the contract terms and the changes will be come into force by specifying the version number and the date of change on time it is published in the "SITE".

 

30.03.2014

Privacy Policy

We recommend you to read the terms of use below before you visit our website. In case you agree these terms, following our rules will be to your favor. Please read our Terms of Use thoroughly.

www.turkiyeklinikleri.com website belongs to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. and is designed in order to inform physicians in the field of health

www.turkiyeklinikleri.com cannot reach to user’s identity, address, service providers or other information. The users may send this information to the website through forms if they would like to. However, www.turkiyeklinikleri.com may collect your hardware and software information. The information consists of your IP address, browser type, operating system, domain name, access time, and related websites. www.turkiyeklinikleri.com cannot sell the provided user information (your name, e-mail address, home and work address, phone number) to the third parties, publish it publicly, or keep it in the website. Gathered information has a directing feature to be a source for the website’s visitor profile, reporting and promotion of the services.

www.turkiyeklinikleri.com uses the taken information:

-To enhance, improve and maintain the quality of the website

-To generate visitor’s profile and statistical data

-To determine the tendency of the visitors on using our website

-To send print publications/correspondences

-To send press releases or notifications through e-mail

-To generate a list for an event or competition

By using www.turkiyeklinikleri.com you are considered to agree that;

-Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. cannot be hold responsible for any user’s illegal and immoral behavior,

-Terms of use may change from time to time,

-It is not responsible for other websites’ contents it cannot control or the harms they may cause although it uses the connection they provided.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. may block the website to users in the following events:

-Information with wrong, incomplete, deceiving or immoral expressions is recorded to the website,

-Proclamation, advertisement, announcement, libelous expressions are used against natural person or legal identity,

-During various attacks to the website,

-Disruption of the website because of a virus.

Written, visual and audible materials of the website, including the code and the software are under protection by legal legislation.

Without the written consent of Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. the information on the website cannot be downloaded, changed, reproduced, copied, republished, posted or distributed.

All rights of the software and the design of the website belong to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. will be pleased to hear your comments about our terms of use. Please share the subjects you think may enrich our website or if there is any problem regarding our website.

info@turkiyeklinikleri.com